136 related articles for article (PubMed ID: 3051231)
41. Recent advances in the adjuvant therapy of breast cancer.
Di Leo A
Tumori; 2000; 86(5 Suppl 1):S11-3. PubMed ID: 11195286
[No Abstract] [Full Text] [Related]
42. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation.
Br J Cancer; 1988 Jun; 57(6):608-11. PubMed ID: 2900647
[TBL] [Abstract][Full Text] [Related]
43. Patients' preferences in randomized clinical trials.
Angell M
N Engl J Med; 1984 May; 310(21):1385-7. PubMed ID: 6717511
[No Abstract] [Full Text] [Related]
44. Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. CRC Adjuvant Breast Trial Working Party.
Br J Cancer; 1988 Jun; 57(6):604-7. PubMed ID: 2900646
[TBL] [Abstract][Full Text] [Related]
45. Trials and tribulations: thoughts on the organisation of multicentre clinical studies.
Br Med J; 1980 Oct; 281(6245):918-20. PubMed ID: 7427509
[TBL] [Abstract][Full Text] [Related]
46. Limited surgical management for primary breast cancer: a commentary on the NSABP reports.
Fisher B; Wolmark N
World J Surg; 1985 Oct; 9(5):682-91. PubMed ID: 3904230
[No Abstract] [Full Text] [Related]
47. Exclusions from clinical trials.
Andersen KW
Eur J Cancer (1965); 1980; Suppl 1():3-4. PubMed ID: 7318867
[No Abstract] [Full Text] [Related]
48. Recruitment to breast cancer trials.
Stewart HJ; Robinson SM
Lancet; 1984 Nov; 2(8411):1096-7. PubMed ID: 6150165
[No Abstract] [Full Text] [Related]
49. Interpretation of results from subset analyses within overviews of randomized clinical trials.
Gelber RD; Goldhirsch A
Stat Med; 1987; 6(3):371-88. PubMed ID: 3616290
[TBL] [Abstract][Full Text] [Related]
50. Future prospectives in the treatment of breast cancer.
Henney JE; DeVita VT
Semin Oncol; 1978 Dec; 5(4):465-8. PubMed ID: 366758
[No Abstract] [Full Text] [Related]
51. Cancer: the failure of treatment.
Haybittle JL; Freedman LS
Br J Radiol; 1988 Feb; 61(722):173-4. PubMed ID: 3349256
[No Abstract] [Full Text] [Related]
52. [Ethical considerations in the treatment of breast cancer].
Tagnon H
Rev Med Brux; 1988; 9(1):13-9. PubMed ID: 3363251
[No Abstract] [Full Text] [Related]
53. Adjuvant systemic therapy in primary breast cancer.
Mouridsen HT; Palshof T
Acta Chir Scand Suppl; 1984; 519():43-53. PubMed ID: 6393664
[No Abstract] [Full Text] [Related]
54. Conservative treatment of breast cancer with QU.A.R.T. Technique.
Veronesi U; Zucali R; Del Vecchio M
World J Surg; 1985 Oct; 9(5):676-81. PubMed ID: 3904229
[No Abstract] [Full Text] [Related]
55. Performing serial testing of treatment effects.
Fleming TR; Green SJ; Harrington DP
Experientia Suppl; 1982; 41():469-84. PubMed ID: 6958531
[No Abstract] [Full Text] [Related]
56. Adjuvant therapy in breast cancer.
Forbes JF
Aust N Z J Surg; 1982 Aug; 52(4):414-7. PubMed ID: 7052042
[No Abstract] [Full Text] [Related]
57. The early results from a randomised study of radiotherapy versus Nolvadex (tamoxifen) as initial treatment for stage III breast cancer.
Williams MR; Gilson D; Marsh L; Morgan DA; Nicholson RI; Elston CW; Griffiths K; Blamey RW
Eur J Surg Oncol; 1988 Jun; 14(3):235-40. PubMed ID: 3371476
[TBL] [Abstract][Full Text] [Related]
58. A prospective study of the treatment of stage III breast cancer.
Spangenberg JP; Nel CJ; Anderson JD; Doman MJ
S Afr J Surg; 1986 Jun; 24(2):57-60. PubMed ID: 3726673
[No Abstract] [Full Text] [Related]
59. Neoadjuvant chemotherapy in the conservative management of breast cancers: study of 143 patients.
Jacquillat CI; Weil M; Auclerc G; Sellami M; Auclerc MF; Khayat D; Baillet F
Recent Results Cancer Res; 1986; 103():113-9. PubMed ID: 3526473
[No Abstract] [Full Text] [Related]
60. [Effect of cytostatic therapy on bone metabolism].
Heytmanek G; Sevelda P; Enzelsberger H; Metka M; Kubista E
Gynakol Rundsch; 1988; 28 Suppl 2():193-5. PubMed ID: 3069624
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
